You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HR negative

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial (Disitamab Vedotin+Anlotinib)

Not yet recruiting
  • Breast Cancer
  • Disitamab Vedotin+Anlotinib
  • (no location specified)
Aug 14, 2023

Breast Tumors Trial in Guangzhou (Trilaciclib, Epirubicin, Cyclophosphamide)

Not yet recruiting
  • Breast Neoplasms
  • Guangzhou, Gangdong, China
    Sun-yat sen university cancer center
Jul 30, 2023

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,

Not yet recruiting
  • HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
  • PERT-IJS plus trastuzumab, carboplatin and docetaxel
  • Perjeta plus trastuzumab, carboplatin and docetaxel
  • (no location specified)
Sep 21, 2023

Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer

Active, not recruiting
  • Hormone-receptor-positive Breast Cancer
  • +2 more
  • No drug
  • Cambridge, Massachusetts
    ConcertAI database
Sep 8, 2023

Breast Cancer Trial in Tianjin (Dalcelli?Exemestane?Gosserine, Docetaxel for injection?Epirubicin HCl for

Recruiting
  • Breast Cancer
  • Tianjin, Tianjin, China
    Jie Ge
Aug 20, 2023

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;

Recruiting
  • Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
  • dalpiciclib; fluvestrant; compound gossypol acetate tablets
  • Hangzhou, Zhejiang, China
    zhejiangCH
Nov 9, 2023

Breast Cancer Trial in Chengdu (Dalpiciclib combined with Letrozole)

Not yet recruiting
  • Breast Cancer
  • Dalpiciclib combined with Letrozole
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Aug 3, 2023

Breast Cancer, Breast Tumors, HER2-positive Breast Cancer Trial in Guanzhou (HLX11, EU-Perjeta®)

Recruiting
  • Breast Cancer
  • +2 more
  • Guanzhou, Guangdong, China
    Sun Yat-Sun Yat-sen Hospital affiliated to Sun Yat-sen Universit
Apr 28, 2022

Breast Cancer Trial (Giredestrant, Abemaciclib, Inavolisib)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Feb 1, 2023

Breast Cancer Trial in Guangzhou (Chidamide Plus Toripalimab Plus Paclitaxel)

Recruiting
  • Breast Cancer
  • Chidamide Plus Toripalimab Plus Paclitaxel
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 19, 2023

HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)

Recruiting
  • HR Positive HER2 Negative Advanced Breast Cancer
  • Tianjin, China
    天津市肿瘤医院
May 26, 2023

HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

Recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Targeted Therapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Aug 1, 2023

Solid Tumor Trial (Dalpiciclib)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Aug 22, 2022

Breast Cancer Trial in Guangzhou (Tucidinostat, Capecitabine, Endocrine Therapy)

Recruiting
  • Breast Cancer
  • Guangzhou, Gangdong, China
    Shusen Wang
Nov 1, 2022

Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,

Not yet recruiting
  • Breast Cancer Invasive
  • +3 more
  • Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
  • Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nov 17, 2023

Breast Cancer Trial in Zhengzhou (Capecitabine+endocrine therapy, Placebo+endocrine therapy)

Recruiting
  • Breast Cancer
  • Capecitabine+endocrine therapy
  • Placebo+endocrine therapy
  • Zhengzhou, Henan, China
    Henan cancer hospital
Nov 19, 2022

Advanced Breast Cancer Trial in Thalassery (Alpelisib, Fulvestrant)

Recruiting
  • Advanced Breast Cancer
  • Thalassery, Kerala, India
    Novartis Investigative Site
Nov 21, 2022

Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor Trial (Elacestrant, Triptorelin)

Not yet recruiting
  • Breast Cancer
  • +3 more
  • (no location specified)
Aug 4, 2023

Advanced HR+ HER2 Negative Breast Carcinoma Trial ((CDK)4/6 inhibitor)

Not yet recruiting
  • Advanced HR+ HER2 Negative Breast Carcinoma
  • (CDK)4/6 inhibitor
  • (no location specified)
Sep 27, 2022

Breast Cancer Trial in Lexington, East Syracuse (TOL2506, Tamoxifen, Letrozole tablets)

Enrolling by invitation
  • Breast Cancer
  • Lexington, Kentucky
  • +1 more
Jan 9, 2023

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Alpelisib, Tamoxifen, Infigratinib)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Stanford, California
    Stanford University
Nov 16, 2022

Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab

Recruiting
  • Locally Advanced or Unresectable Metastatic Breast Cancer
  • Stage IV Breast Cancer
  • Sacituzumab Govitecan-hziy
  • +3 more
  • Marietta, Georgia
  • +1 more
Apr 21, 2023

Breast Cancer, Metastatic Cancer Trial (SHR-1316, SHR6390, Nab paclitaxel)

Not yet recruiting
  • Breast Cancer
  • Metastatic Cancer
  • (no location specified)
Jan 11, 2022

HR+, HER2-, Advanced Breast Cancer Trial (alpelisib)

Available
  • HR+, HER2-, Advanced Breast Cancer
  • (no location specified)
Jul 5, 2022

Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Tuebingen, Germany
      Department of Women's Health
    Jun 1, 2023